Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. (GBT): 6 pipeline candidates · ~37 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
36.8 months
D/E 6.35 · 0% dilution
Lead: Approved
6 candidates
N/A
N/A
A transparent, data-derived signal for Global Blood Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$263.6M
Quarterly Burn
$44.3M
Runway
36.8 mo
Revenue
$71.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Frequently asked questions
How many drug candidates are in Global Blood Therapeutics, Inc.'s pipeline?
Global Blood Therapeutics, Inc. (GBT) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Global Blood Therapeutics, Inc.'s lead drug candidate?
Global Blood Therapeutics, Inc.'s most advanced tracked candidate is carisolv non-invasive dental caries removal system (Approved) for Dental.
What is Global Blood Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Global Blood Therapeutics, Inc. has approximately 36.8 months of cash runway.
Who is the CEO of Global Blood Therapeutics, Inc.?
South San Francisco is the chief executive officer of Global Blood Therapeutics, Inc. (GBT).
Get the full picture on Global Blood Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.